Keay Nakae

Stock Analyst at Chardan Capital

(4.44)
# 312
Out of 5,090 analysts
251
Total ratings
46.09%
Success rate
26.91%
Average return

Stocks Rated by Keay Nakae

Arrowhead Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $60
Current: $61.43
Upside: -2.32%
Allurion Technologies
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.70
Upside: +47.49%
SAB Biotherapeutics
Nov 17, 2025
Maintains: Buy
Price Target: $12
Current: $3.99
Upside: +200.75%
Arbutus Biopharma
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.45
Upside: +12.49%
Coya Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $14
Current: $6.00
Upside: +133.33%
Monopar Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $100
Current: $81.34
Upside: +22.95%
Orchestra BioMed Holdings
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.41
Upside: +353.51%
Korro Bio
Nov 13, 2025
Downgrades: Neutral
Price Target: $25$7
Current: $7.02
Upside: -0.28%
Avidity Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $71.76
Upside: +0.33%
ProQR Therapeutics
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $2.08
Upside: +92.31%
Maintains: Buy
Price Target: $35
Current: $6.98
Upside: +401.43%
Maintains: Buy
Price Target: $325$400
Current: $458.55
Upside: -12.77%
Maintains: Buy
Price Target: $50$38
Current: $20.27
Upside: +87.47%
Maintains: Buy
Price Target: $5
Current: $1.20
Upside: +316.67%
Downgrades: Neutral
Price Target: $1.25$6
Current: $16.59
Upside: -63.83%
Maintains: Buy
Price Target: $6
Current: $3.82
Upside: +57.07%
Maintains: Buy
Price Target: $10$8
Current: $0.88
Upside: +808.16%
Downgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Maintains: Sell
Price Target: $8$6
Current: $17.94
Upside: -66.56%
Maintains: Buy
Price Target: $1,140$380
Current: $5.15
Upside: +7,278.64%
Maintains: Buy
Price Target: $65$55
Current: $11.87
Upside: +363.35%
Maintains: Neutral
Price Target: $1.25$10
Current: $4.98
Upside: +100.80%
Upgrades: Neutral
Price Target: $100$88
Current: $20.00
Upside: +337.50%
Downgrades: Neutral
Price Target: $0.7$13
Current: $1.23
Upside: +961.22%